Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test

Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test

Objectives To investigate the role of third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in predicting progression to inflammatory arthritis (IA) in individuals with new musculoskeletal (MSK) symptoms and a negative second-generation anti-CCP antibody test (anti-CCP2−).Methods...

Full description

Bibliographic Details
Main Authors: Kulveer Mankia, Paul Emery, Michael Mahler, Andrea Di Matteo, Laurence Duquenne, Leticia Garcia-Montoya, Jacqueline L Nam, Sana Sharrack
Format: Article
Language:English
Published: BMJ Publishing Group 2024-04-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/10/2/e003927.full

Internet

https://rmdopen.bmj.com/content/10/2/e003927.full

Similar Items